Advertisement
U.S. markets close in 33 minutes
Advertisement

Vaxxinity, Inc. (VAXX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Visitors trend2W10W9M
0.8500-0.0790 (-8.50%)
As of 03:26PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Performance Outlook
Previous Close0.9290
Open0.9158
Bid0.8600 x 800
Ask0.8699 x 900
Day's Range0.8500 - 0.9181
52 Week Range0.8000 - 4.4700
Volume704,363
Avg. Volume229,620
Market Cap107.734M
Beta (5Y Monthly)3.14
PE Ratio (TTM)N/A
EPS (TTM)-0.5300
Earnings DateNov 08, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for VAXX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Vaxxinity, Inc.
    Daily – Vickers Top Buyers & Sellers for 01/07/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    2 years agoArgus Research
View more
  • Reuters

    FOCUS-Researchers return to Alzheimer's vaccines, buoyed by recent drug success

    Breakthrough Alzheimer’s treatments that remove toxic proteins from the brain have revived interest in vaccines to treat the memory-robbing disease, potentially offering a cheaper, easy-to-administer option for millions of people, according to interviews with 10 scientists and company executives. Clinical trials are underway or completed for at least seven Alzheimer’s vaccines designed to harness the immune system to rid the brain of the disease-related proteins beta amyloid or tau, a review of the U.S. government’s ClinicalTrials.gov database found. The renewed interest in Alzheimer's vaccines follows a promising first attempt more than 20 years ago that was abandoned after 6% of study volunteers developed life-threatening brain inflammation known as meningoencephalitis.

  • GlobeNewswire

    Vaxxinity to Present at Upcoming November Medical and Investor Conferences

    CAPE CANAVERAL, Fla., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that its scientists and executives will present and participate in meetings at three upcoming medical and investor conferences in November. Vaccines Summit – 2023Date: Tuesday, November 14, 2023 Time: 12:20 – 12:40 p.m. (ET)Title: UB-612: A novel peptide/protein subunit COVID-19 vaccine booster stimulated broadly neutralizi

  • GlobeNewswire

    Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update

    CAPE CANAVERAL, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update. “We continue to advance our clinical programs and to validate our platform with the goal of addressing major chronic diseases with more convenient, cost-effective, and accessible immunotherapies worldwide. This quarter, we have